Market Place
Sourcing Support
FORE Biotherapeutics to Participate in Upcoming Nov Conferences
07 Nov 2024 //
BUSINESSWIRE
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
04 Sep 2024 //
BUSINESSWIRE
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
12 Aug 2024 //
BUSINESSWIRE
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer
29 Feb 2024 //
BUSINESSWIRE
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
01 Feb 2024 //
BUSINESSWIRE
FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Conference
07 Dec 2023 //
BUSINESSWIRE
FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data
10 Nov 2023 //
BUSINESSWIRE
FORE Biotherapeutics to Present Plixorafenib Nonclinical Data
12 Oct 2023 //
BUSINESSWIRE
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
23 Aug 2023 //
BUSINESSWIRE
FORE to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib
26 May 2023 //
BUSINESSWIRE
FORE Biotherapeutics Announces 2 Abstracts Accepted for Presentation at the 2023
26 Apr 2023 //
BUSINESSWIRE
FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394
20 Mar 2023 //
BUSINESSWIRE
Fore Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394
23 Feb 2023 //
BUSINESSWIRE
Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394
29 Sep 2022 //
BUSINESSWIRE
Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394
12 Sep 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.